From Publishers Weekly
Rosenberg, chief of surgery at the National Cancer Institute, details the years of clinical and laboratory research that led to his developing the controversial cancer therapy using interleukin-2 (IL-2), a protein produced by the human immune system and synthesized in the lab. Treatment involves withdrawing a patient's cancer-killing white blood cells, mixing them with immune-activating IL-2 and injecting the mixture back into the body. Publicized by the medical establishment and the media as a breakthrough, IL-2 has, as Rosenberg notes here, severe side effects and cures only a minority of patients afflicted with only a few kinds of cancer. In addition, two critics of the medical establishment, Jane Heimlich ( What Your Doctor Won't Tell You ) and Ralph Moss ( The Cancer Industry ), have pointed out that IL-2 is prohibitively expensive and that treatment with it may require many weeks of hospitalization. Rosenberg also discusses his work on gene therapy, an experimental modality in which genetically altered white blood cells are reinserted in the cancer patient's bloodstream to attack the tumor. One feels that he overstates the promise of both types of treatment. Photos.
Copyright 1992 Reed Business Information, Inc.
--This text refers to an out of print or unavailable edition of this title.
From Library Journal
In this exciting book, Rosenberg, chief of surgery at the National Cancer Institute and author of dozens of books and papers on cancer, uses his own experience of seeking new treatments for cancer patients to explain how scientists conduct medical research. Telling of the scientific dream to use the body's immune system to cure cancer, he discusses how the past decade has witnessed the attempt to treat cancer by manipulating natural host biologic functions using recombinant DNA technology, interleukin-2, interferon, and colony-stimulating factors. Using engrossing case histories, Rosenberg, a caring and sensitive expert, shares with his readers the agonizing successes and failures of advanced therapies that promise to join surgery, radiation therapy, and chemotherapy as a fourth major treatment approach for cancer patients. Highly recommended.
- James Swanton, Albert Einstein Coll. of Medicine, New YorkCopyright 1992 Reed Business Information, Inc.
--This text refers to an out of print or unavailable edition of this title.